1. Kern U., Martin C., Scheicher S., Müller H. (2003)

Treatment of phantom pain with botulinum-toxin A.

A pilot study; Schmerz 17, 117-124

2. Kern U., Martin C., Scheicher S., Müller H. (2004)

Long-term treatment of phantom- and stump pain with Botulinum toxin type A

over 12 months. A first clinical observation. Nervenarzt 75, 336-340

3. Kern U., Martin C., Scheicher S., Müller H. (2006)

Referred pain from amputation stump trigger points into the phantom limb.

Schmerz 20, 300, 302-306

4. Kern U., Busch V., Rockland M., Kohl M., Birklein F. (2009)

Prevalence and risk factors of phantom limb pain and phantom limb sensations in Germany. A nationwide field survey. Schmerz 23, 479-488

5. Kern U., Kohl M., Kiefer R.-T. (2010)

Lidocaine patch for therapy of neuropathic and non-neuropathic pain: A clinical case series of 87 patients. Nervenarzt 81, 1490-1497

6. Kern U., Altkemper B., Kohl M. (2006)

Management of phantom pain with a textile, electromagnetically-acting stump liner: a randomized, double-blind, crossover study. J Pain Symptom Manage

32, 352-360

7. Kern U., Kohl M., Seifert U., Schlereth T. (2011)

Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study. Am J Phys Med Rehabil 90, 321-329

8. Kern U., Martin C., Scheicher S., Müller H. (2003)

Botulinum toxin type A influences stump pain after limb amputations.

J Pain Symptom Manage 26, 1069-1070

9. Kern U., Martin C., Scheicher S., Müller H. (2004)

Effects of botulinum toxin type B on stump pain and involuntary movements of the stump. Am J Phys Med Rehabil 83, 396-399

10. Kern U. (2004)

Influence of botulinum toxin on postamputation pain and phantom limbs.

J Neurol Feb 251 Suppl 1, I/42

11.  Kern U., Martin C., Scheicher S., Müller H. (2004)

Does botulinum toxin A make prosthesis use easier for amputees?

J Rehabil Med 36, 238-239

12. Koch H., Kern U., Busch V. (2009)

Therapeutische Wirkung von Ausdauersport bei Migräne: Explorative

Metaanalyse sportmedizinischer Studien.

MMW-Forschritte der Medizin Originalien Nr.II, 59-62

13. Reilich P., Fheodoroff K., Kern U., 

Mense S., Seddigh S., Wissel J., et al. (2004)

Consensus statement: botulinum toxin in myofascial pain.

J Neurol 251 Suppl 1, I36-38

14. England J., Wagner T., Kern U., Roth-Daniek A., Sell A. (2011)

The capsaicin 8% patch for peripheral neuropathic pain: practical guidance,

hints and tips on the application process. Br J Nurs. 2011 Aug 11-Sep

8;20(15):926-31

15. Kern U., Kohl M., Seifert U., Schlereth T. (2012)

Botulinumtoxin Typ B lindert Stumpfschmerzen und Stumpfschwitzen -

Chance zur indirekten Phantomschmerz-Reduktion durch bessere Prothesen-

Nutzung?

Schmerz. 2012 Apr;26(2):176-84

16. Kern U., Busch V., Mueller R., Kohl M., Birklein F. (2012)

Phantom limb pain in daily pratice - still a lot of work to do!

Pain Med. 2012 Sep 26. doi:10.1111/j.1526-4637.2012.01494.x

17. Mick G., Baron R., Kern U., Hans G., Finnerup N. B., Dworkin R. H. (2011)

Localized neuropathic pain: clinical characteristics and a proposed definition.

Pain Manage. (2012) 2(1), 71–77

18. Wagner T., Roth-Daniek A., Sell A., England J., Kern U. (2012)

The capsaicin 8% patch for peripheral neuropathic pain: Review of treatment

best practice from ‚real world‘ clinical experience. Pain Manage 2012;2:

239-250

19. Kern U., Nolte T. (2008)

25 years of progress in pain therapy: the rocky road to recognition.

MMW Fortschr Med 150, 115-117

20. Kiefer T.-R., Kern U., Bredanger S. (2008)

Chronische Knieschmerzen: ein außergewöhnlicher Fall.

Angewandte Schmerztherapie 2, 45-48

21. Kern U. (2006)

Botulinumtoxin beim myofaszialen Schmerzsyndrom.

Schmerztherapie Nr.1 18-19

22. Kern U., in Fayyaz A., Jost W.-H. (ed.) (2003)

BTX - A in the treatment of Phantom Pain.

Wissenschaftsverlag Wellingsbüttel Hamburg

23. Kern U., in Junker U., Nolte T. (ed.) (2005)

Grundlagen der speziellen Schmerztherapie.

Verlag Medizin & Wissen, München

24. Kern U., in Ningel R., Funke W. (ed.) (1995)

Soziale Netzwerke in der Praxis. Verlag für angewandte Psychologie,

Göttingen

25. Busch V., Magerl W., Kern U., Haas J., Hajak G., Eichhammer P. (2012)

The effect of deep and slow breathing on pain perception, autonomic activity

and mood processing. An experimental study. Pain Med. 2012

Feb;13(2):215-28

26. Kern U., England J., Roth-Daniek A., Wagner T. (2013)

Is physician supervision of the capsaicin 8% patch administration procedure

really necessary? An opinion from health care professionals. J Pain Res. 2013

Jul 19;6:571-5

27. Kern U., Nalamachu S., Brasseur L., Zakrzewska J.-M. (2013)

Can treatment success with 5% lidocaine medicated plaster be predicted in

cancer pain with neuropathic components or trigeminal neuropathic pain?

J Pain Res. 2013 Apr 5;6:261-80

28. Kern U., Bialas P., Fangmann D. (2013)

Prolonged-release tapentadol for phantom pain. A case series.

Schmerz. 2013 Apr 27;(2):174-81

29. Treede R.-D., Wagner T., Kern U., Husstedt I.-W., Arendt G., Birklein F.,

Freynhagen R., Gockel H.-H., Heskamp M.-L., Jager H., Joppich R., Maier C.,

Leffler A., Nagelein H.-H., Rolke R., Seddigh S., Sommer C., Stander S.,

Wasner G., Baron R. (2013)

Mechanism- and experience-based strategies to optimize treatment response

to the capsaicin 8% cutaneous patch in patients with localized neuropathic

pain.

Curr Med Res Opin. 2013 May 29&;(5):527-38

30. Baron R., Kern U., Müller M., Dubois C., Falke D., Steigerwald I. (2014)

Effectiveness and olerability of a Moderate Dose of Tapentadol Prolonged

Release for Managing Severe, Chronic Low Back Pain with a Neuropathic

Component: An Open-label Continuation Arm of a Randomized Phase 3b

Study.Pain Pract. 2014 Apr 18

31. Kern U., Nowack W., Poole C. (2014)

Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment

with lidocaine necessary? Pain Pract. 2014 Feb 14;(2):E42-50

32. Baron R, Kern U, Muller M et al. (2015)

Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged

Release for Managing Severe, Chronic Low Back Pain with a Neuropathic

Component: An Open-label Continuation Arm of a Randomized Phase 3b

Study. Pain practice : the official journal of World Institute of Pain 15:471-486

33. Kern KU, Baust H, Hofmann W et al. (2014)

Capsaicin 8 % cutaneous patches for phantom limb pain. Results from

everyday practice (non-interventional study). Schmerz 28:374-383

34. Kern KU, Bialas P, Fangmann D (2013)

Prolonged-release tapentadol for phantom pain. A case series.

Schmerz 27:174-181

35. Kern KU, England J, Roth-Daniek A et al. (2013)

Is physician supervision of the capsaicin 8% patch administration procedure

really necessary? An opinion from health care professionals.

Journal of pain research 6:571-575

36. Kern KU, Krings D, Waldmann-Rex S (2014)

Tapentadol prolonged release improves analgesia, functional impairment and

quality of life in patients with chronic pain who have previously received

oxycodone/naloxone. MMW Fortschritte der Medizin 156 Suppl 2:54-63

37. Kern KU, Nalamachu S, Brasseur L et al. (2013)

Can treatment success with 5% lidocaine medicated plaster be predicted in

cancer pain with neuropathic components or trigeminal neuropathic pain?

Journal of pain research 6:261-280

38. Kern KU, Nowack W, Poole C (2014)

Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment

with lidocaine necessary?

Pain practice : the official journal of World Institute of Pain 14:E42-50

39. Sanchez Del Aguila MJ, Schenk M, Kern KU et al. (2015)

Practical considerations for the use of tapentadol prolonged release for the

management of severe chronic pain. Clinical therapeutics 37:94-113

40. Schlereth T, Heiland A, Breimhorst M et al. (2015)

Association between pain, central sensitization and anxiety 

in postherpetic neuralgia.

European journal of pain 19:193-201

41. Treede RD, Wagner T, Kern KU et al. (2013)

Mechanism- and experience-based strategies to optimize treatment response

to the capsaicin 8% cutaneous patch in patients with localized neuropathic

pain.

Current medical research and opinion 29:527-538

42. Kern KU, Weiser T. (Dec. 2015)

Topical ambroxol for the treatment of neuropathic pain: 

A first clinical observation.

German version. Schmerz, 29(6):632-40

43. Kern KU, Weiser T. (dec. 2015)

Topical ambroxol for the treatment of neuropathic pain : An initial clinical

observation. English version Schmerz, 29(Suppl 3):89-96

44. Kern U (2013)

Komponenten der Analgesie durch Akupunktur spezifiziert (Kommentar).

JC Schmerzmed 2:213

45. Kern U (2014)

Die Faktoren für chronische Schmerzen nach Brustkrebs-OP (Kommentar).

JC Schmerzmed 3:76-76

46. Kern U (2015)

Medikamentöse Kombinationstherapie bei Polyneuropathie (Kommentar).

JC Schmerzmed 4:157-157

47. Kern U (2015)

Schmerzlinderung durch Berührung: Mechanismen genauer entschlüsselt

(Kommentar). JC Schmerzmed 3:83

48. Kern U (2016)

Pharmakotherapie neuropathischer Schmerzen; 

Topische Therapien ergänzen bewährte systemische Konzepte.

Deutsche Apothekerzeitung 156:46-52

49. Kern U (2016)

Neuraltherapeutische Injektionstechniken bei Rückenschmerz (Kommentar).

JC Schmerzmed 5:129-129

50. Baron R, Eberhart L, Kern KU et al. (2016)

Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials

and 5 Years of Routine Clinical Practice Data. Pain Pract. 2017

Jun;17(5):678-700

51. Kern U (2016)

Lokaltherapie mit Lidocain u. therapeutische Lokalanästhesie (Kap. 5);

Lokaltherapie mit speziellen Substanzen (Kap. 7). In: Moderne Praxis der

analgetischen Lokaltherapie, UNI-MED Science, 1. Aufl. (Editor C. Maihöfner)

52. Kern KU, Schwickert-Nieswandt M, Maihöfner C, Gaul C (2019)

Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia - A

New Option? Initial Clinical Case Observations. Headache. 2019

Mar;59(3):418-429

53. Maihöfner C, Schneider S, Bialas P, Gockel H, Beer KG, Bartels M, Kern KU

(2018)

Successful treatment of complex regional pain syndrome with topical

ambroxol: a case series. Pain Manag. 2018 Nov 1;8(6):427-436

54. Poehlke T, Gralow I, Kern U et al. (2017)

Empfehlungen zur Substitutionstherapie mit Buprenorphin/Naloxon bei

behandlungsbedürftiger Medikamentenabhängigkeit von Opioiden.

Sonderveröffentlichung

55. Baron R, Treede RD, Birklein F et al. (2017)

Treatment of painful radiculopathies with capsaicin 8% cutaneous patch.

Current medical research and opinion:1-25

56. Kern U, Krings D, Waldmann-Rex S (2017)

Tapentadol Prolonged Release Improves Analgesia, Functional Impairment

and Quality of Life in Patients with Chronic Pain who have Previously

Received Oxycodone/Naloxone. J Pain Relief 6:281.

57. Kern KU, Schwickert M (2017)

Ambroxol for the treatment of fibromyalgia: science or fiction?

Journal of pain research 10:1905-1929

58. Kern KU, Schwickert-Nieswandt M (2019)

Postherpetic neuralgia of the left trigeminus nerve V1: Successful therapy with

capsaicin 8% patch.

Schmerz 2018 Dec;32(6):464-467

59. Kern KU (2019)

Update Orthopädie, Hot Topic: Schmerz. Orthopade 2019 Apr;48(4):348-349

60. Kern KU, Sohns M, Heckes B, Elling C. (2020)

Tapentadol prolonged release for severe chronic osteoarthritis pain in the

elderly: improvements in daily functioning and quality of life.

Pain Manag. 2020 Mar;10(2):85-95

61. Kraus M, Lintzeris N, Bhaskar A, Alho H, Alon E, Bouhassira D, Haro G,

D‘Agnone O, Dematteis M, Kern KU, Maremmani I, Perrot S, Sittl R, Pellicano

K. (2020)

Consensus and Controversies Between Pain and Addiction Experts on the

Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder.

J Addict Med. 2020 Jan/Feb;14(1):1-11

62. Mit einem Bein bereits im Himmel (2020)

Phantomwahrnehmungen - auf den Spuren eines rätselhaften Phänomens

Kai-Uwe Kern, Hogrefe Verlag, ISBN 978-3-456-86013-8

63. Huygen F, Kern KU, Pérez C. (2020)

Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179

mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral

Neuropathic Pain.

J Pain Res. 2020 Oct 14;13:2585-2597

64. Schubert T., Kern K.-U., Schneider S., Baron R. (2021)

Oral or Topical Pain Therapy - How Would Patients Decide? A Discrete Choice

Experiment in Patients with Peripheral Neuropathic Pain.

Pain Pract. 2021 Jun;21(5):536-546

65. Swidan S (Herausgeber), Bennett M (Herausgeber), (2020)

Kern KU (Chapter author ‚Fibromyalgia‘) In: Advanced Therapeutics in Pain

Medicine

CRC Press; 1. Edition (Dec 2020)

66. Kern U. (2019)

Hochdosiertes Capsaicin-Pflaster in der Behandlung peripherer

neuropathischer Schmerzen. Ein Erfahrungsbericht mit 58 Patienten.

Psychopharmakotherapie, 2012. 19: p. 72-5

67. Kern K.-U., Vogelmann T., Tölle T. R. (2022)

Tapentadol versus klassische WHO-III-Opioide 

bei chronischen Rückenschmerzen

Versorgungsforschungsstudie auf Basis repräsentativer Krankenkassendaten

MMW-Fortschritte der Medizin 2022; 164 (S6): 19–27

68. Russo M.-A., Baron R., Dickenson A.-H., Kern K.-U., Santarelli D.-M. (2023)

Ambroxol for neuropathic pain: hiding in plain sight?

Pain. 2023 Jan 1;164(1):3-13

69. Kern K.-U. (2023)

Low back pain management in routine clinical practice: what is important for

the individual patient? Pain Manag. 2023 Apr;13(4):243-252

70. Kern K.-U., Quandel T., Theis S., Schubert T. (2024)

Characteristics and outcomes of peripheral neuropathic pain patients with

repeated applications of high-concentration capsaicin cutaneous patch:

Results of a retrospective chart review in Germany.

Pain Pract. 2024;00:1–9.

71. Kern K.-U., (2025)

Heimweh nach Glück

Lyrische Texte für Menschen mit Schmerzen in Körper und Seele, 

Verlag BoD, ISBN-9783819257230